Rigosertib Completed Phase 2 Trials for Splenomegaly / Agnogenic Myeloid Metaplasia / Anemias / Leukemias Treatment

IndicationsStatusPurposePhase
CompletedTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT02730884Single-Arm Study of the Efficacy and Safety of Oral Rigosertib in Patients With Myelofibrosis (MF) and Anemia